FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/21/2023
Back to search
Official data from USPTO
BERGENBIO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
54
Latest update
11/21/2023
Trademark type
Combined
Nice classes
1, 5, 42
Filing date
10/22/2021
Registration date
08/01/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/01/2023
Last transaction
08/01/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
63
Owner location
NO
Examiner
BARRETT, LEAH N
Law office
L60
Current location
TMEG LAW OFFICE 106
Mark description
The mark consists of the stylized wording "BERGENBIO" to the right of a design of 6 shaded circles and one outlined hexagon arranged in an overall hexagonal shape.
Holders and representatives
Holders
B. A. (pessoa física)
Representatives
James M. Theo Dinsmore & Shohl LLP
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical preparationschemical compoundsbiochemical preparations and biologic compounds for scientific or industrial purposesfor use in laboratories or in research; chemical preparationschemical compoundsbiochemical preparations and biologic compounds for analytical and diagnostic purposes in laboratory use; chemical preparationschemical compoundsbiochemical preparations and biologic compounds for the experimental production of drugspharmaceutical products and biotechnological preparations; chemical preparationschemical compoundsbiochemical preparations and biologic compounds for use in the development and manufacture of diagnostic products and servicesdrugs and pharmaceutical productsthe diagnosis and treatment of cancersincluding lung cancerleukaemiaaggressive cancersimmune evasive cancers and metastatic cancers; chemical preparationschemical compoundsbiochemical preparations and biologic compounds for use in the development and manufacture of drugs and pharmaceutical productsdrugs and pharmaceutical products that target axlakt3 or other genesproteinskinases and enzymes; active chemical and biochemical ingredients and components for use in the development and manufacture of diagnostic products and servicesdrugs and pharmaceutical productsfor the diagnosis and treatment of cancersincluding lung cancerleukaemiaaggressive cancersimmune evasive cancers and metastatic cancers; antibodiessmall molecules and proteins for scientific or industrial purposesfor use in laboratories or in research; antibodiessmall molecules and proteins for use in the development and manufacture of diagnostic products and servicesdrugs and pharmaceutical productsfor the diagnosis and treatment of cancersincluding lung cancerleukaemiaaggressive cancersimmune evasive cancers and metastatic cancers; antibodiessmall molecules and proteins for use in the development and manufacture of drugs and pharmaceutical productsdrugs and pharmaceutical products that target axlakt3 or other genesproteinskinases and enzymes; antibodiesanti-axl antibodiessmall moleculessmall molecules that inhibit axl kinaseselective inhibitorsselective axl inhibitorsselective axl kinase inhibitors and selective inhibitors of cell surface proteins for scientific or industrial purposesfor use in laboratories or in research; antibodiesanti-axl antibodiessmall moleculessmall molecules that inhibit axl kinaseselective inhibitorsselective axl inhibitorsselective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of diagnostic products and servicesdrugs and pharmaceutical productsfor the diagnosis and treatment of cancersincluding lung cancerleukaemiaaggressive cancersimmune evasive cancers and metastatic cancers; antibodiesanti-axl antibodiessmall moleculessmall molecules that inhibit axl kinaseselective inhibitorsselective axl inhibitorsselective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of drugs and pharmaceutical productsdrugs and pharmaceutical products that target axlakt3 or other genesproteinskinases and enzymes; proteins for use in kinase inhibiting technologyfor scientific purposes
Class 5
Drugs and pharmaceutical products for medical purposesmedications for the treatment of cancer and severe respiratory infections; drugs and pharmaceutical products for medical purposes incorporating antibodiesanti-axl antibodiessmall moleculessmall molecules that inhibit axl kinaseselective inhibitorsselective axl inhibitorsselective axl kinase inhibitorsselective inhibitors of cell surface proteinsmedications for the treatment of cancer and severe respiratory infections; drugs and pharmaceutical products for medical purposesfor use in oncology and for the treatment of cancerslung cancerleukaemiaaggressive cancersimmune evasive cancers and metastatic cancers; drugs and pharmaceutical products that target axlakt3 or other genesproteinskinases and enzymes; chemical preparationschemical compoundsbiochemical preparations and biologic compounds for medical purposes; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for medical laboratory analysis; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease testingthe testing for lung cancerleukaemiaaggressive cancersimmune evasive cancersmetastatic cancers and severe respiratory infections; antibodiessmall molecules and proteins for medical purposes; antibodiesanti-axl antibodiessmall moleculessmall molecules that inhibit axl kinaseselective inhibitorsselective axl inhibitorsselective axl kinase inhibitors and selective inhibitors of cell surface proteins for medical purposes; protein synthesis inhibitors for medical purposes
Class 42
Drug discovery and pharmaceutical drug development services; scientific research services; research and development services in the fields of oncology and immunology; scientific research services related to the role of axl and related kinase signalling in disease; scientific research services related to axl biology and its role in mediating aggressive disease; scientific research services related to biomarker discovery; scientific research services related to the development of diagnostic products and servicesin the field of treatment of cancersincluding lung cancerleukaemiaaggressive cancersimmune evasive cancers and metastatic cancers; scientific research services related to improving the efficacy of chemotherapytargeted cancer therapy and immunooncology drugs; research and development services in the field of antibodiessmall molecules and proteins; conducting and providing research and development services for others in the field of antibody and small molecule technology; medical and biotechnology research services; researchdevelopment and engineering of antibodiessmall molecules and proteinsanti-axl antibodiessmall molecules that inhibit axl kinaseselective inhibitorsselective axl inhibitorsselective axl kinase inhibitors and selective inhibitors of cell surface proteins; laboratory research services relating to the production of antibodiessmall molecules and proteinsanti-axl antibodiessmall molecules that inhibit axl kinaseselective inhibitorsselective axl inhibitorsselective axl kinase inhibitors and selective inhibitors of cell surface proteins; researching and developing the use of antibodiessmall molecules and proteins for the treatment of patients; informationconsultancy and advisory services related to the aforesaid services
Publications
History of USPTO decisions and trademark events.
54 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/01/2023
FIMP
FINAL DISPOSITION PROCESSED
11/01/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/01/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/01/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
08/01/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
06/26/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/07/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
06/07/2023
GPNX
NOTIFICATION PROCESSED BY IB
05/17/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/16/2023
PUBO
PUBLISHED FOR OPPOSITION
05/16/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/26/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/26/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/26/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/10/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/05/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/05/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/05/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/28/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/28/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/28/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/28/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/28/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/28/2023
GNRT
NON-FINAL ACTION E-MAILED
02/28/2023
CNRT
NON-FINAL ACTION WRITTEN
02/28/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
02/05/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/26/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/26/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/26/2023
RFNT
REFUSAL PROCESSED BY IB
01/24/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/04/2023
RFRR
REFUSAL PROCESSED BY MPU
01/04/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/18/2022
CNRT
NON-FINAL ACTION WRITTEN
10/17/2022
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
10/11/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/11/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/11/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/11/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/11/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/11/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/09/2022
CNRT
NON-FINAL ACTION WRITTEN
08/08/2022
DOCK
ASSIGNED TO EXAMINER
08/01/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/17/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/17/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/17/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/17/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/17/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/05/2022
MAFR
APPLICATION FILING RECEIPT MAILED
01/11/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/07/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/06/2022
Continuous trademark protection
Get notified about every new filing that threatens BERGENBIO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.